bosentan anhydrous has been researched along with Pulmonary Embolism in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (46.15) | 29.6817 |
| 2010's | 13 (50.00) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Kelder, JC; Mager, JJ; Post, MC; Snijder, RJ; Ten Klooster, L; van Thor, MCJ | 1 |
| Jiang, X; Jing, ZC; Xu, XQ | 1 |
| Halank, M; Held, M; Igarashi, T; Kunihara, T; Nomura, R; Sata, F; Schäfers, HJ; Wilkens, H | 1 |
| Gaine, SP; Murphy, DM; Murphy, DT; Murray, JG | 1 |
| Cannon, JE; Pepke-Zaba, J | 1 |
| Bresser, P; Kloek, JJ; Marcus, JT; Reesink, HJ; Surie, S; van der Plas, MN; Vonk-Noordegraaf, A | 1 |
| Adachi, S; Hirashiki, A; Kondo, T; Kono, Y; Morimoto, R; Murohara, T; Nakano, Y; Okumura, T; Shimazu, S; Shimizu, S; Takeshita, K; Yamada, S | 1 |
| Kario, K; Nishikawa-Takahashi, M; Ueno, S | 1 |
| Cebotari, S; Hoeper, MM; Madani, MM; Meyer, B; Nakanishi, N; Rubin, LJ | 1 |
| Lejnieks, A; Lesina, K; Rudzitis, A; Sablinskis, K; Skride, A | 1 |
| Channick, R; Jais, X; Pepke-Zaba, J | 1 |
| Cassandro, R; Confalonieri, M; Harari, S; Kodric, M; Piattella, M; Potena, A; Scarda, A; Scarduelli, C; Vassallo, FG | 1 |
| Kostrubiec, M; Pedowska-Włoszek, J; Pruszczyk, P | 1 |
| Saxena, S; Spangler, ML | 1 |
| Agnelli, G; Becattini, C; Busti, C; Gennarini, S; Manina, G | 1 |
| Kähler, CM | 1 |
| Caballero Eraso, C; Elías Hernández, T; Ferrer Galván, M; Jara Palomares, L; López Villalobos, JL; Otero Candelera, R | 1 |
| Hughes, R; Humbert, M; Jais, X; Parent, F; Pepke-Zaba, J; Simonneau, G; Suntharalingam, J | 1 |
| Christopoulos, A; Kourouklis, S; Kyriakides, ZS; Liagkas, K; Paradellis, G | 1 |
| Casset-Sedon, D; Cosnay, P; Maillot, F; Pierre, B; Regina, S; Sitbon, O | 1 |
| Wilkens, H | 1 |
| Alonso-Pulpón Rivera, L; Gómez Bueno, M; González González, M; Moñivas Palomero, V; Ortiz Uribe, JC; Segovia Cubero, J | 1 |
| Auger, WR; Fedullo, PF; Kerr, KM; Kim, NH; Test, VJ | 1 |
| Brentjens, TE; Bulman, W; Coyle, CM; Dickstein, ML; Emond, J; Horn, EM; Kawut, SM; Wilt, JS | 1 |
| Aubert, JD; Domenighetti, G; Fischler, M; Geiser, T; Huber, L; Rochat, T; Speich, R; Treder, U; Ulrich, S | 1 |
| Channick, RN; Chiles, PG; Kim, H; Konopka, RG; Marsh, JJ; Morris, TA; Pedersen, CA; Yung, GL | 1 |
8 review(s) available for bosentan anhydrous and Pulmonary Embolism
| Article | Year |
|---|---|
Is distal chronic thromboembolic pulmonary hypertension treatable with PAH targeted drugs?
Topics: Antihypertensive Agents; Bosentan; Chronic Disease; Compassionate Use Trials; Endarterectomy; Humans; Hypertension, Pulmonary; Piperazines; Pulmonary Embolism; Purines; Pyrazoles; Pyrimidines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome | 2013 |
Chronic thromboembolic pulmonary hypertension.
Topics: Angioplasty, Balloon; Bosentan; Chronic Disease; Endarterectomy; Endothelin Receptor Antagonists; Enzyme Activators; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Piperazines; Pulmonary Embolism; Purines; Pyrazoles; Pyrimidines; Sildenafil Citrate; Sulfonamides; Thromboembolism | 2014 |
Medical Therapy in Chronic Thromboembolic Pulmonary Hypertension.
Topics: Bosentan; Chronic Disease; Comorbidity; Endarterectomy; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Pulmonary Embolism; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Recurrence; Secondary Prevention; Sulfonamides | 2016 |
[Potential role of endothelin in patients with acute pulmonary embolism and chronic thromboembolic pulmonary hypertension].
Topics: Acute Disease; Antihypertensive Agents; Bosentan; Chronic Disease; Endothelins; Humans; Hypertension, Pulmonary; Pulmonary Embolism; Sulfonamides | 2009 |
Bosentan for chronic thromboembolic pulmonary hypertension: findings from a systematic review and meta-analysis.
Topics: Antihypertensive Agents; Bosentan; Case-Control Studies; Chronic Disease; Cohort Studies; Double-Blind Method; Hemodynamics; Humans; Hypertension; Hypertension, Pulmonary; Pulmonary Embolism; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome; Vascular Resistance | 2010 |
Current understanding of the role of bosentan in inoperable chronic thromboembolic pulmonary hypertension.
Topics: Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Drug Administration Schedule; Endothelin Receptor Antagonists; Endothelin-1; Humans; Hypertension, Pulmonary; Pulmonary Embolism; Receptors, Endothelin; Sulfonamides | 2006 |
[Pulmonary arterial hypertension following pulmonary thromboembolism].
Topics: Antihypertensive Agents; Bosentan; Endarterectomy; Humans; Hypertension, Pulmonary; Iloprost; Piperazines; Pulmonary Embolism; Purines; Recurrence; Sildenafil Citrate; Splenectomy; Sulfonamides; Sulfones; Vasodilator Agents | 2006 |
Chronic thromboembolic pulmonary hypertension.
Topics: Antibodies, Antiphospholipid; Bosentan; Cardiac Catheterization; Chronic Disease; Endarterectomy; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Physical Exertion; Pulmonary Embolism; Risk Factors; Sulfonamides; Thrombectomy | 2007 |
4 trial(s) available for bosentan anhydrous and Pulmonary Embolism
| Article | Year |
|---|---|
Bosentan treatment is associated with improvement of right ventricular function and remodeling in chronic thromboembolic pulmonary hypertension.
Topics: Aged; Antihypertensive Agents; Bosentan; Endarterectomy; Exercise Test; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Magnetic Resonance Imaging; Male; Middle Aged; Netherlands; Pilot Projects; Pulmonary Embolism; Recovery of Function; Single-Blind Method; Sulfonamides; Time Factors; Treatment Outcome; Ventricular Dysfunction, Right; Ventricular Function, Left; Ventricular Function, Right; Ventricular Remodeling; Waiting Lists | 2013 |
Bosentan for patients with chronic thromboembolic pulmonary hypertension.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antihypertensive Agents; Bosentan; Chronic Disease; Diuretics; Drug Therapy, Combination; Dyspnea; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prospective Studies; Pulmonary Embolism; Sulfonamides; Treatment Outcome; Walking; Young Adult | 2009 |
[Role of bosentan in patients with chronic venous thromboembolic pulmonary hypertension].
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Chronic Disease; Data Interpretation, Statistical; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Embolism; Retrospective Studies; Sulfonamides; Time Factors; Treatment Outcome | 2007 |
Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonar
Topics: Aged; Antihypertensive Agents; Bosentan; Chronic Disease; Endothelin Receptor Antagonists; Exercise Tolerance; Female; Health Status Indicators; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Pulmonary Embolism; Quality of Life; Severity of Illness Index; Sulfonamides | 2007 |
14 other study(ies) available for bosentan anhydrous and Pulmonary Embolism
| Article | Year |
|---|---|
Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?
Topics: Aged; Bosentan; Chronic Disease; Drug Therapy, Combination; Endarterectomy; Endothelin Receptor Antagonists; Enzyme Activators; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Phosphodiesterase 5 Inhibitors; Pulmonary Embolism; Pyrazoles; Pyrimidines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Survival Rate; Walk Test | 2019 |
The Key Laboratory of Pulmonary Vascular Medicine, Chinese Academy of Medical Sciences (KLPVM-CAMS).
Topics: Academies and Institutes; Administration, Inhalation; Angioplasty, Balloon; Antihypertensive Agents; Asian People; Bone Morphogenetic Protein Receptors, Type II; Bosentan; Calcium Channel Blockers; Cardiology; Cooperative Behavior; Endothelin Receptor Antagonists; Female; Growth Differentiation Factor 2; Guidelines as Topic; Humans; Iloprost; Mutation; Phenylpropionates; Pulmonary Arterial Hypertension; Pulmonary Embolism; Pulmonary Medicine; Pyridazines; Takayasu Arteritis; Vasodilator Agents | 2019 |
Haemodynamic benefit of bridging use of bosentan prior to pulmonary endarterectomy.
Topics: Bosentan; Chronic Disease; Endarterectomy; Hemodynamics; Humans; Hypertension, Pulmonary; Pulmonary Artery; Pulmonary Embolism; Treatment Outcome | 2021 |
Case 1: chronic thromboembolic pulmonary hypertension (CTEPH).
Topics: Adult; Anticoagulants; Antihypertensive Agents; Bosentan; Chronic Disease; Diuretics; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Male; Pulmonary Embolism; Sulfonamides; Tomography, X-Ray Computed; Warfarin | 2013 |
Cardiopulmonary exercise testing to evaluate the exercise capacity of patients with inoperable chronic thromboembolic pulmonary hypertension: an endothelin receptor antagonist improves the peak PETCO2.
Topics: Bosentan; Carbon Dioxide; Endothelin Receptor Antagonists; Exercise; Exercise Test; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Oxygen; Pulmonary Embolism; Sulfonamides; Ultrasonography; Vascular Resistance | 2014 |
Long-term advanced therapy with bosentan improves symptoms and prevents deterioration of inoperable chronic thromboembolic pulmonary hypertension.
Topics: Asian People; Bosentan; Chronic Disease; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Japan; Male; Middle Aged; Pulmonary Embolism; Sulfonamides; Time Factors | 2014 |
First data from Latvian chronic thromboembolic pulmonary hypertension registry.
Topics: Adult; Age Distribution; Aged; Anticoagulants; Bosentan; Chronic Disease; Female; Humans; Hypertension, Pulmonary; Incidence; Latvia; Male; Middle Aged; Phenylpropionates; Prevalence; Pulmonary Embolism; Pyrazoles; Pyridazines; Pyridones; Registries; Rivaroxaban; Sex Distribution; Sildenafil Citrate; Sulfonamides; Vasodilator Agents; Warfarin; Young Adult | 2016 |
Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli.
Topics: Anticoagulants; Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Bosentan; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Hypertension, Pulmonary; International Normalized Ratio; Middle Aged; Pulmonary Embolism; Sulfonamides; Treatment Outcome; Warfarin | 2010 |
Chronic thromboembolic pulmonary hypertension as a cause of dyspnoea in an older patient with a complex history.
Topics: Antihypertensive Agents; Bosentan; Chronic Disease; Dyspnea; Endarterectomy; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Embolism; Sulfonamides; Tomography, Spiral Computed | 2009 |
Chronic thromboembolic pulmonary hypertension due to upper-extremity deep vein thrombosis caused by thoracic outlet syndrome.
Topics: Antihypertensive Agents; Arm; Asthma; Bosentan; Cardiac Catheterization; Dyspnea; Female; Humans; Hypertension, Pulmonary; Pulmonary Embolism; Smoking; Sulfonamides; Syncope; Thoracic Outlet Syndrome; Thrombophlebitis; Young Adult | 2012 |
Bosentan in Eisenmenger syndrome and chronic thromboembolic pulmonary hypertension.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Chronic Disease; Down Syndrome; Echocardiography, Doppler; Eisenmenger Complex; Endothelin Receptor Antagonists; Female; Humans; Male; Middle Aged; Pulmonary Embolism; Sulfonamides; Treatment Outcome | 2006 |
[Chronic pulmonary thromboembolism revealing beta-thalassemia intermedia after splenectomy].
Topics: Antihypertensive Agents; beta-Thalassemia; Bosentan; Chronic Disease; Humans; Iron Overload; Male; Middle Aged; Pulmonary Embolism; Splenectomy; Sulfonamides; Treatment Outcome | 2006 |
Severe pulmonary hypertension due to chronic echinococcal pulmonary emboli treated with targeted pulmonary vascular therapy and hepatic resection.
Topics: Adult; Antihypertensive Agents; Bosentan; Chronic Disease; Echinococcosis, Hepatic; Echinococcosis, Pulmonary; Epoprostenol; Hepatectomy; Humans; Hypertension, Pulmonary; Male; Pulmonary Artery; Pulmonary Embolism; Sulfonamides; Thoracic Surgery, Video-Assisted; Vena Cava, Inferior | 2007 |
Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension.
Topics: Analysis of Variance; Animals; Antihypertensive Agents; Bosentan; Chronic Disease; Culture Techniques; Disease Models, Animal; Dogs; Endothelin-1; Female; Hemodynamics; Hypertension, Pulmonary; Immunohistochemistry; Lung; Male; Probability; Pulmonary Artery; Pulmonary Circulation; Pulmonary Embolism; Reference Values; Sulfonamides; Tomography, Emission-Computed; Vascular Resistance | 2000 |